clozapine Flashcards
6 indications de clozapine à part schizophrénie résistante
manie résistante (add)
psychose chez parkinson
agressivité
suicidalité
polydipsie psychogène
dyskinésie tardive
traitement de non réponse a la clozapine
verifier adhérence
verifier niveaux plasmatiques et augmenter la dose (seuil minimal 350 ng/ml, aller ad 1000 ng/ml si toléré)
ajouter un AP avec D2 effect
ajouter ECT
work up avant debuter clozapine
signes vitaux
BMI
constipation? smoking? seizures?
labs: FSC (neutro, eosino), E+/creat/liver/HbA1C/lipids
ECG (QT)
abd XR if needed
insciption au programme de suivi de clozapine
QT correction error: how to estimate the true QT at rate >72/sec
current formula (Bazett) overestimates QT
Fridericia formula QTc=QT/racine cube du RR
titration clozapine inpatient smoker/non smoker
titration pour smoker (non smoker - 50%)
se rendre à 200 en 1 sem et 400 en 2 sem
25-50-100-150-200
ensuite par increment de 50 mg (par 2-3 jours) ad 400
dosage clozapine 7 jours apres 400mg
titration clozapine pour outpatient smoker/non smoker
doses pour smoker (non smoker - 50% de la dose)
ad 100 jour6
ad 200 jour12
ad 300 jour18
ad 400 jour24
dosage plasmatique 7 jours apres 300mg
à quel delais d’attendre de la myocardite?
1-7 weeks after initiation of Tx, most cases - within 4 weeks
monitoring after initiaion of clozapine
within 3 months - possible side effects
then - FSC
8 side effects of clozapine
neutropenia
constipation - ileus
sedation
orthostasis - tachycardia
sialorrhea
seizure
metabolic syndrome
DRESS syndrome
constipating medications - psychotrops
chlorpromazine +++
olanzapine
quetiapine >600
TCA
antiparkinsonian: cogentin, diphenhydramine
constipating medications - non psychotrops
opiods
iron
managing cholinergic rebound
si possible, baisser la dose par 100 mg die ad 100mg die
ensuite - par increments de 25 mg q 4-7 jours
if sleep disturbance - 25-50 mg benadryl HS
if abrupt d/c - strart cogentin (benztropine) at equivalent dose (50 mg clozapine in nonsmoker = 1 mg cogentin = 25 mg benadryl) for at least 2 weeks
options pour pts parkinson sous clozapine si d/c
pimavanserin (nuplazid) - a first-in-class atypical antipsychotic that does not induce clinically significant antagonism of dopaminergic, adrenergic, histaminergic, or muscarinic receptors. It is the first FDA-approved drug indicated for the treatment of the hallucinations and delusions in PD-associated psychosis
possibly - quetiapine
ECT
options pour pts parkinson sous clozapine si d/c
pimavanserin (nuplazid) - a first-in-class atypical antipsychotic that does not induce clinically significant antagonism of dopaminergic, adrenergic, histaminergic, or muscarinic receptors. It is the first FDA-approved drug indicated for the treatment of the hallucinations and delusions in PD-associated psychosis
possibly - quetiapine
ECT
mechanisme d’action - clozapine
alpha 1 antagonist
H1 antagonist
M1 et M3 antagonism
norclozapine - agonist M1-M5 exept M3 (donne sialorrhea via agonisme muscarinique)
D2 antagost (low affinity)
5HT2A - inverse agonist